Skip to main content
Erschienen in: Metabolic Brain Disease 6/2023

23.03.2023 | Original Article

Complete Loss of Myelin protein zero (MPZ) in a patient with a late onset Charcot-Marie-Tooth (CMT)

verfasst von: Jalal Gharesouran, Hassan Hosseinzadeh, Ali Naghiloo, Soudeh Ghafouri-Fard, Bashdar Mahmud Hussen, Mohammad Taheri, Maryam Rezazadeh, Mohammad Samadian

Erschienen in: Metabolic Brain Disease | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Charcot-Marie-Tooth (CMT) comprises a group of hereditary neuropathies with clinical, epidemiological, and molecular heterogeneity in which variants in more than 80 different genes have been reported. One of the important genes which cause 5% of all CMT cases is Myelin protein zero (P0, MPZ). Variants in this gene have been reported in association with different forms of CMT including classical CMT1, severe DSS (CMT3B), DI-CMT, CMT2I and CMT2J with autosomal dominant (AD) inheritance. To our knowledge, MPZ variants have not been described in autosomal recessive (AR) form of CMT in previous studies. Moreover, its complete deletion has not been reported in human. Here, we described clinical characteristics of a patient with CMT symptoms who demonstrated manifestations of the disease late in his life. We performed exome sequencing for identifying CMT subtype and its associated gene, and follow that co-segregation analysis has been done to characterize inheritance pattern of the disorder. Through using exome sequencing, we identified a novel 4074 bp homozygote deletion which encompasses all 6 exons of the MPZ gene in this patient. After identifying the alteration, variant confirmation and co-segregation analysis have been performed by using specific primers. Our result revealed that the patient’s parents were heterozygous for the alteration and they did not show any symptoms of CMT. Although most MPZ variants have been described with early onset CMT with AD pattern of inheritance, the reported patient in our study had late onset form and his parents did not show any symptoms. Considering substantial role of MPZ protein in the biogenesis of peripheral nervous system (PNS) myelin, we proposed that there should be another protein in PNS that compensates for lack of MPZ protein. Taken together, our finding is the first report of MPZ association with AR form of CMT with late onset features. Moreover, our results propose the presence of another protein in PNS myelin biogenesis and its assembly. However, functional studies alongside with other molecular studies are needed to confirm our results and identify the proposed protein.
Literatur
Zurück zum Zitat Antonellis A, Dennis MY, Burzynski G, Huynh J, Maduro V, Hodonsky CJ, Khajavi M, Szigeti K, Mukkamala S, Bessling SL (2010) A rare myelin protein zero (MPZ) variant alters enhancer activity in vitro and in vivo. PLoS One 5:e14346CrossRefPubMedPubMedCentral Antonellis A, Dennis MY, Burzynski G, Huynh J, Maduro V, Hodonsky CJ, Khajavi M, Szigeti K, Mukkamala S, Bessling SL (2010) A rare myelin protein zero (MPZ) variant alters enhancer activity in vitro and in vivo. PLoS One 5:e14346CrossRefPubMedPubMedCentral
Zurück zum Zitat Azevedo H, Pupe C, Pereira R, Nascimento OJ (2018) Pain in Charcot-Marie-Tooth disease: an update. Arq Neuropsiquiatr 76:273–276CrossRefPubMed Azevedo H, Pupe C, Pereira R, Nascimento OJ (2018) Pain in Charcot-Marie-Tooth disease: an update. Arq Neuropsiquiatr 76:273–276CrossRefPubMed
Zurück zum Zitat Beckett J, Holden J, Simpson N, White B, Macleod P (1986) Localization of X-linked dominant Charcot-Marie-Tooth disease (CMT 2) to Xq13. J Neurogenet 3:225–231CrossRefPubMed Beckett J, Holden J, Simpson N, White B, Macleod P (1986) Localization of X-linked dominant Charcot-Marie-Tooth disease (CMT 2) to Xq13. J Neurogenet 3:225–231CrossRefPubMed
Zurück zum Zitat Bergoffen J, Scherer S, Wang S, Scott MO, Bone L, Paul D, Chen K, Lensch M, Chance P, Fischbeck K (1993) Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 262:2039–2042CrossRefPubMed Bergoffen J, Scherer S, Wang S, Scott MO, Bone L, Paul D, Chen K, Lensch M, Chance P, Fischbeck K (1993) Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 262:2039–2042CrossRefPubMed
Zurück zum Zitat Bird T, Ott J, Giblett E (1982) Evidence for linkage of Charcot-Marie-Tooth neuropathy to the Duffy locus on chromosome 1. Am J Hum Genet 34:388PubMedPubMedCentral Bird T, Ott J, Giblett E (1982) Evidence for linkage of Charcot-Marie-Tooth neuropathy to the Duffy locus on chromosome 1. Am J Hum Genet 34:388PubMedPubMedCentral
Zurück zum Zitat Birouk N, Gouider R, Le Guern E, Gugenheim M, Tardieu S, Maisonobe T, Le Forestier N, Agid Y, Brice A, Bouche P (1997) Charcot-Marie-Tooth disease type 1A with 17p11 2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 120:813–823 Birouk N, Gouider R, Le Guern E, Gugenheim M, Tardieu S, Maisonobe T, Le Forestier N, Agid Y, Brice A, Bouche P (1997) Charcot-Marie-Tooth disease type 1A with 17p11 2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 120:813–823
Zurück zum Zitat Blair IP, Nash J, Gordon MJ, Nicholson GA (1996) Prevalence and origin of de novo duplications in Charcot-Marie-Tooth disease type 1A: first report of a de novo duplication with a maternal origin. Am J Hum Genet 58:472PubMedPubMedCentral Blair IP, Nash J, Gordon MJ, Nicholson GA (1996) Prevalence and origin of de novo duplications in Charcot-Marie-Tooth disease type 1A: first report of a de novo duplication with a maternal origin. Am J Hum Genet 58:472PubMedPubMedCentral
Zurück zum Zitat Braathen G (2012) Genetic epidemiology of C harcot–M arie–T ooth disease. Acta Neurol Scand 126:iv–22CrossRef Braathen G (2012) Genetic epidemiology of C harcot–M arie–T ooth disease. Acta Neurol Scand 126:iv–22CrossRef
Zurück zum Zitat Carenini S, Neuberg D, Schachner M, Suter U, Martini R (1999) Localization and functional roles of PMP22 in peripheral nerves of P0-deficient mice. Glia 28:256–264CrossRefPubMed Carenini S, Neuberg D, Schachner M, Suter U, Martini R (1999) Localization and functional roles of PMP22 in peripheral nerves of P0-deficient mice. Glia 28:256–264CrossRefPubMed
Zurück zum Zitat Choi B-O, Kim S-B, Kanwal S, Hyun YS, Park SW, Koo H, Yoo JH, Hyun JW, Park KD, Choi K-G (2011) MPZ mutation in an early-onset Charcot-Marie-Tooth disease type 1B family by genome-wide linkage analysis. Int J Mol Med 28:389–396PubMed Choi B-O, Kim S-B, Kanwal S, Hyun YS, Park SW, Koo H, Yoo JH, Hyun JW, Park KD, Choi K-G (2011) MPZ mutation in an early-onset Charcot-Marie-Tooth disease type 1B family by genome-wide linkage analysis. Int J Mol Med 28:389–396PubMed
Zurück zum Zitat De Sèze J, Kremer L, Do Rego CA, Taleb O, Lam D, Beiano W, Mensah-Nyagan G, Trifilieff E, Brun S (2016) Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. Rev Neurol 172:767-769 De Sèze J, Kremer L, Do Rego CA, Taleb O, Lam D, Beiano W, Mensah-Nyagan G, Trifilieff E, Brun S (2016) Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. Rev Neurol 172:767-769
Zurück zum Zitat Fasano A, Amoresano A, Rossano R, Carlone G, Carpentieri A, Liuzzi GM, Pucci P, Riccio P (2008) The different forms of PNS myelin P0 protein within and outside lipid rafts. J Neurochem 107:291–301CrossRefPubMed Fasano A, Amoresano A, Rossano R, Carlone G, Carpentieri A, Liuzzi GM, Pucci P, Riccio P (2008) The different forms of PNS myelin P0 protein within and outside lipid rafts. J Neurochem 107:291–301CrossRefPubMed
Zurück zum Zitat Filbin MT, Walsh FS, Trapp BD, Pizzey JA, Tennekoon GI (1990) Role of myelin Po protein as a homophilic adhesion molecule. Nature 344:871–872CrossRefPubMed Filbin MT, Walsh FS, Trapp BD, Pizzey JA, Tennekoon GI (1990) Role of myelin Po protein as a homophilic adhesion molecule. Nature 344:871–872CrossRefPubMed
Zurück zum Zitat Garbay B, Heape A, Sargueil F, Cassagne C (2000) Myelin synthesis in the peripheral nervous system. Prog Neurobiol 61:267–304CrossRefPubMed Garbay B, Heape A, Sargueil F, Cassagne C (2000) Myelin synthesis in the peripheral nervous system. Prog Neurobiol 61:267–304CrossRefPubMed
Zurück zum Zitat Han H, Myllykoski M, Ruskamo S, Wang C, Kursula P (2013) Myelin-specific proteins: A structurally diverse group of membrane-interacting molecules. BioFactors 39:233–241CrossRefPubMed Han H, Myllykoski M, Ruskamo S, Wang C, Kursula P (2013) Myelin-specific proteins: A structurally diverse group of membrane-interacting molecules. BioFactors 39:233–241CrossRefPubMed
Zurück zum Zitat Hasse B, Bosse F, Hanenberg H, Müller HW (2004) Peripheral myelin protein 22 kDa and protein zero: domain specific trans-interactions. Mol Cell Neurosci 27:370–378CrossRefPubMed Hasse B, Bosse F, Hanenberg H, Müller HW (2004) Peripheral myelin protein 22 kDa and protein zero: domain specific trans-interactions. Mol Cell Neurosci 27:370–378CrossRefPubMed
Zurück zum Zitat Inouye H, Kirschner DA (2016) Evolution of myelin ultrastructure and the major structural myelin proteins. Brain Res 1641:43–63CrossRefPubMed Inouye H, Kirschner DA (2016) Evolution of myelin ultrastructure and the major structural myelin proteins. Brain Res 1641:43–63CrossRefPubMed
Zurück zum Zitat Lee S, Amici S, Tavori H, Zeng WM, Freeland S, Fazio S, Notterpek L (2014) PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts. J Neurosci 34:16140–16152CrossRefPubMedPubMedCentral Lee S, Amici S, Tavori H, Zeng WM, Freeland S, Fazio S, Notterpek L (2014) PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts. J Neurosci 34:16140–16152CrossRefPubMedPubMedCentral
Zurück zum Zitat Lousa M, Vázquez-Huarte-mendicoa C, Gutiérrez AJ, Saavedra P, Navarro B, Tugores A (2019) Genetic epidemiology, demographic, and clinical characteristics of Charcot-Marie-tooth disease in the island of Gran Canaria (Spain). J Peripher Nerv Syst 24:131–138CrossRefPubMed Lousa M, Vázquez-Huarte-mendicoa C, Gutiérrez AJ, Saavedra P, Navarro B, Tugores A (2019) Genetic epidemiology, demographic, and clinical characteristics of Charcot-Marie-tooth disease in the island of Gran Canaria (Spain). J Peripher Nerv Syst 24:131–138CrossRefPubMed
Zurück zum Zitat Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, Bainbridge M, Dinh H, Jing C, Wheeler DA (2010) Whole-genome sequencing in a patient with Charcot–Marie–Tooth neuropathy. N Engl J Med 362:1181-1191 Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, Bainbridge M, Dinh H, Jing C, Wheeler DA (2010) Whole-genome sequencing in a patient with Charcot–Marie–Tooth neuropathy. N Engl J Med 362:1181-1191
Zurück zum Zitat Magy L, Mathis S, le Masson G, Goizet C, Tazir M, Vallat J-M (2018) Updating the classification of inherited neuropathies: results of an international survey. Neurology 90:e870–e876CrossRefPubMed Magy L, Mathis S, le Masson G, Goizet C, Tazir M, Vallat J-M (2018) Updating the classification of inherited neuropathies: results of an international survey. Neurology 90:e870–e876CrossRefPubMed
Zurück zum Zitat Murphy SM, Laura M, Fawcett K, Pandraud A, Liu Y-T, Davidson GL, Rossor AM, Polke JM, Castleman V, Manji H (2012) Charcot–Marie–Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 83:706–710CrossRefPubMed Murphy SM, Laura M, Fawcett K, Pandraud A, Liu Y-T, Davidson GL, Rossor AM, Polke JM, Castleman V, Manji H (2012) Charcot–Marie–Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 83:706–710CrossRefPubMed
Zurück zum Zitat Nicolaou P, Christodoulou K (2013) Advances in the molecular diagnosis of Charcot-Marie-Tooth disease. World J Neurol 3:42–55CrossRef Nicolaou P, Christodoulou K (2013) Advances in the molecular diagnosis of Charcot-Marie-Tooth disease. World J Neurol 3:42–55CrossRef
Zurück zum Zitat Oliveira J, Negrão L, Fineza I, Taipa R, Melo-Pires M, Fortuna AM, Gonçalves AR, Froufe H, Egas C, Santos R (2015) New splicing mutation in the choline kinase beta (CHKB) gene causing a muscular dystrophy detected by whole-exome sequencing. J Hum Genet 60:305–312CrossRefPubMed Oliveira J, Negrão L, Fineza I, Taipa R, Melo-Pires M, Fortuna AM, Gonçalves AR, Froufe H, Egas C, Santos R (2015) New splicing mutation in the choline kinase beta (CHKB) gene causing a muscular dystrophy detected by whole-exome sequencing. J Hum Genet 60:305–312CrossRefPubMed
Zurück zum Zitat Raasakka A, Ruskamo S, Kowal J, Han H, Baumann A, Myllykoski M, Fasano A, Rossano R, Riccio P, Bürck J (2019) Molecular structure and function of myelin protein P0 in membrane stacking. Sci Rep 9:1–15CrossRef Raasakka A, Ruskamo S, Kowal J, Han H, Baumann A, Myllykoski M, Fasano A, Rossano R, Riccio P, Bürck J (2019) Molecular structure and function of myelin protein P0 in membrane stacking. Sci Rep 9:1–15CrossRef
Zurück zum Zitat Reilly MM, Murphy SM, Laura M (2011) Charcot-Marie-Tooth disease. J Peripher Nerv Syst 16:1–14CrossRefPubMed Reilly MM, Murphy SM, Laura M (2011) Charcot-Marie-Tooth disease. J Peripher Nerv Syst 16:1–14CrossRefPubMed
Zurück zum Zitat Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME (2011) Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 69:22–33CrossRefPubMedPubMedCentral Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME (2011) Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 69:22–33CrossRefPubMedPubMedCentral
Zurück zum Zitat Shy ME (2006) Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci 242:55–66CrossRefPubMed Shy ME (2006) Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci 242:55–66CrossRefPubMed
Zurück zum Zitat Shy ME, Jáni A, Krajewski K, Grandis M, Lewis RA, Li J, Shy RR, Balsamo J, Lilien J, Garbern JY (2004) Phenotypic clustering in MPZ mutations. Brain 127:371–384CrossRefPubMed Shy ME, Jáni A, Krajewski K, Grandis M, Lewis RA, Li J, Shy RR, Balsamo J, Lilien J, Garbern JY (2004) Phenotypic clustering in MPZ mutations. Brain 127:371–384CrossRefPubMed
Zurück zum Zitat Siems SB, Jahn O, Eichel MA, Kannaiyan N, Wu LMN, Sherman DL, Kusch K, Hesse D, Jung RB, Fledrich R (2020) Proteome profile of peripheral myelin in healthy mice and in a neuropathy model. Elife 9:e51406CrossRefPubMedPubMedCentral Siems SB, Jahn O, Eichel MA, Kannaiyan N, Wu LMN, Sherman DL, Kusch K, Hesse D, Jung RB, Fledrich R (2020) Proteome profile of peripheral myelin in healthy mice and in a neuropathy model. Elife 9:e51406CrossRefPubMedPubMedCentral
Zurück zum Zitat Td B (2019) Charcot‐Marie‐Tooth (CMT) Hereditary Neuropathy Overview. 1998 Sep 28 [Updated 2019 Jan 24]. GeneReviews®[Internet]. University of Washington, Seattle (WA) Td B (2019) Charcot‐Marie‐Tooth (CMT) Hereditary Neuropathy Overview. 1998 Sep 28 [Updated 2019 Jan 24]. GeneReviews®[Internet]. University of Washington, Seattle (WA)
Zurück zum Zitat Thomas P, Marques Jr W, Davis M, Sweeney M, King R, Bradley J, Muddle J, Tyson J, Malcolm S, Harding A (1997) The phenotypic manifestations of chromosome 17p11. 2 duplication. Brain 120:465–478 Thomas P, Marques Jr W, Davis M, Sweeney M, King R, Bradley J, Muddle J, Tyson J, Malcolm S, Harding A (1997) The phenotypic manifestations of chromosome 17p11. 2 duplication. Brain 120:465–478
Zurück zum Zitat Vance J, Nicholson G, Yamaoka L, Stajich J, Stewart C, Speer M, Hung W-Y, Roses A, Barker D, Pericak-Vance M (1989) Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol 104:186–189CrossRefPubMed Vance J, Nicholson G, Yamaoka L, Stajich J, Stewart C, Speer M, Hung W-Y, Roses A, Barker D, Pericak-Vance M (1989) Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol 104:186–189CrossRefPubMed
Zurück zum Zitat Wrabetz L, Feltri ML, Quattrini A, Imperiale D, Previtali S, D’Antonio M, Martini R, Yin X, Trapp BD, Zhou L (2000) P0 glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 148:1021–1034CrossRefPubMedPubMedCentral Wrabetz L, Feltri ML, Quattrini A, Imperiale D, Previtali S, D’Antonio M, Martini R, Yin X, Trapp BD, Zhou L (2000) P0 glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 148:1021–1034CrossRefPubMedPubMedCentral
Zurück zum Zitat Xu W, Manichella D, Jiang H, Vallat JM, Lilien J, Baron P, Scarlato G, Kamholz J, Shy ME (2000) Absence of P0 leads to the dysregulation of myelin gene expression and myelin morphogenesis. J Neurosci Res 60:714–724CrossRefPubMed Xu W, Manichella D, Jiang H, Vallat JM, Lilien J, Baron P, Scarlato G, Kamholz J, Shy ME (2000) Absence of P0 leads to the dysregulation of myelin gene expression and myelin morphogenesis. J Neurosci Res 60:714–724CrossRefPubMed
Zurück zum Zitat Yin X, Baek RC, Kirschner DA, Peterson A, Fujii Y, Nave K-A, Macklin WB, Trapp BD (2006) Evolution of a neuroprotective function of central nervous system myelin. J Cell Biol 172:469–478CrossRefPubMedPubMedCentral Yin X, Baek RC, Kirschner DA, Peterson A, Fujii Y, Nave K-A, Macklin WB, Trapp BD (2006) Evolution of a neuroprotective function of central nervous system myelin. J Cell Biol 172:469–478CrossRefPubMedPubMedCentral
Zurück zum Zitat Yin X, Kidd GJ, Nave K-A, Trapp BD (2008) P0 protein is required for and can induce formation of Schmidt-Lantermann incisures in myelin internodes. J Neurosci 28:7068–7073CrossRefPubMedPubMedCentral Yin X, Kidd GJ, Nave K-A, Trapp BD (2008) P0 protein is required for and can induce formation of Schmidt-Lantermann incisures in myelin internodes. J Neurosci 28:7068–7073CrossRefPubMedPubMedCentral
Zurück zum Zitat Yoshida M, Colman D (1996) Parallel evolution and coexpression of the proteolipid proteins and protein zero in vertebrate myelin. Neuron 16:1115–1126CrossRefPubMed Yoshida M, Colman D (1996) Parallel evolution and coexpression of the proteolipid proteins and protein zero in vertebrate myelin. Neuron 16:1115–1126CrossRefPubMed
Metadaten
Titel
Complete Loss of Myelin protein zero (MPZ) in a patient with a late onset Charcot-Marie-Tooth (CMT)
verfasst von
Jalal Gharesouran
Hassan Hosseinzadeh
Ali Naghiloo
Soudeh Ghafouri-Fard
Bashdar Mahmud Hussen
Mohammad Taheri
Maryam Rezazadeh
Mohammad Samadian
Publikationsdatum
23.03.2023
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 6/2023
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-023-01201-x

Weitere Artikel der Ausgabe 6/2023

Metabolic Brain Disease 6/2023 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.